Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2

Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation

“…The application of FDA-approved drugs for cancer treatment has been a hotspot for studying pharmacokinetics, establishing safety in humans, and evaluating toxicity 31 , 32 . Consequently, it may be an intriguing strategy to utilize FDA-approved drugs for ESCC treatment, and several drugs have been demonstrated to have anti-cancer effect in ESCC, such as dasabuvir 48 (for hepatitis C virus treatment), azelnidipine 49 (for hypertension), penfluridol 50 (an antipsychotic drug), and antitussive 51 (an antitussive agent). In this study, we identified an FDA-approved drug, dexrazoxane, as a potential anti-cancer drug for ESCC both in vitro and in vivo.…”

An integrated analysis of dysregulated SCD1 in human cancers and functional verification of miR-181a-5p/SCD1 axis in esophageal squamous cell carcinoma

“…In Asia, approximately 90% of EC patients are diagnosed with ESCC 3 , 4 . ESCC is a highly invasive cancer and more than 50% of ESCC patients have been diagnosed at advanced stages 5 , 6 . Smoking, alcohol consumption, betel nut chewing, chemical factors, infection, and family ESCC history are significantly well-established risk factors for developing ESCC 7 , 8 .…”

Azelnidipine may be a valuable drug for chemoprevention of ESCC with high MEK1/2 levels

“…found that Azelnidipine, which is an anti-hypertensive drug, significantly inhibited the growth of ESCC. 4 It has been reported that Azelnidipine used in colorectal cancer immunotherapy showed significant inhibition on the growth of colorectal cancer by enhancing the quantity and activity of CD8 + T cells in the tumors. 4 However, the mechanism of how Azelnidipine inhibits the proliferation of ESCC is to be studied.…”

“… 4 It has been reported that Azelnidipine used in colorectal cancer immunotherapy showed significant inhibition on the growth of colorectal cancer by enhancing the quantity and activity of CD8 + T cells in the tumors. 4 However, the mechanism of how Azelnidipine inhibits the proliferation of ESCC is to be studied. This study provides a theoretical basis for clinical application of Azelnidipine on ESCC.…”